Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 222

1.

Caloric vestibular stimulation for the management of motor and non-motor symptoms in parkinson's disease: Intention-to-treat data.

Wilkinson D, Podlewska A, Banducci SE, Pellat-Higgins T, Slade M, Bodani M, Sakel M, Smith L, LeWitt P, Ade K.

Data Brief. 2019 Jul 8;25:104228. doi: 10.1016/j.dib.2019.104228. eCollection 2019 Aug.

2.
3.

Caloric vestibular stimulation for the management of motor and non-motor symptoms in Parkinson's disease.

Wilkinson D, Podlewska A, Banducci SE, Pellat-Higgins T, Slade M, Bodani M, Sakel M, Smith L, LeWitt P, Ade KK.

Parkinsonism Relat Disord. 2019 May 31. pii: S1353-8020(19)30252-4. doi: 10.1016/j.parkreldis.2019.05.031. [Epub ahead of print]

4.

Subcutaneous Administration of Carbidopa Enhances Oral Levodopa Pharmacokinetics: A Series of Studies Conducted in Pigs, Mice, and Healthy Volunteers.

Shaltiel-Karyo R, Caraco Y, Zawaznik E, Weinstock I, Nemas M, Oren S, Yacoby-Zeevi O, LeWitt PA.

Clin Neuropharmacol. 2019 Jul/Aug;42(4):111-116. doi: 10.1097/WNF.0000000000000345.

PMID:
31192808
5.

Pharmacokinetics and efficacy of a novel formulation of carbidopa-levodopa (Accordion Pill®) in Parkinson's disease.

LeWitt PA, Giladi N, Navon N.

Parkinsonism Relat Disord. 2019 May 22. pii: S1353-8020(19)30253-6. doi: 10.1016/j.parkreldis.2019.05.032. [Epub ahead of print]

PMID:
31176632
6.

Focused ultrasound opening of the blood-brain barrier for treatment of Parkinson's disease.

LeWitt PA, Lipsman N, Kordower JH.

Mov Disord. 2019 May 28. doi: 10.1002/mds.27722. [Epub ahead of print]

PMID:
31136023
7.

Post-traumatic Origin of Unilateral Restless Leg Syndrome.

LeWitt PA.

Mov Disord Clin Pract. 2018 Mar 23;5(3):323-324. doi: 10.1002/mdc3.12594. eCollection 2018 May-Jun. No abstract available.

8.

Safety and efficacy of CVT-301 (levodopa inhalation powder) on motor function during off periods in patients with Parkinson's disease: a randomised, double-blind, placebo-controlled phase 3 trial.

LeWitt PA, Hauser RA, Pahwa R, Isaacson SH, Fernandez HH, Lew M, Saint-Hilaire M, Pourcher E, Lopez-Manzanares L, Waters C, Rudzínska M, Sedkov A, Batycky R, Oh C; SPAN-PD Study Investigators.

Lancet Neurol. 2019 Feb;18(2):145-154. doi: 10.1016/S1474-4422(18)30405-8. Erratum in: Lancet Neurol. 2019 Mar;18(3):e2.

PMID:
30663606
9.

Comparison of the Fahn-Tolosa-Marin Clinical Rating Scale and the Essential Tremor Rating Assessment Scale.

Ondo W, Hashem V, LeWitt PA, Pahwa R, Shih L, Tarsy D, Zesiewicz T, Elble R.

Mov Disord Clin Pract. 2017 Nov 23;5(1):60-65. doi: 10.1002/mdc3.12560. eCollection 2018 Jan-Feb.

10.

Delayed Hypersensitivity Reaction to OnabotulinumtoxinA.

LeWitt PA.

Mov Disord Clin Pract. 2018 Mar 9;5(3):321-322. doi: 10.1002/mdc3.12575. eCollection 2018 May-Jun.

11.

Nighttime Sleep and Daytime Sleepiness Improved With Pimavanserin During Treatment of Parkinson's Disease Psychosis.

Patel N, LeWitt P, Neikrug AB, Kesslak P, Coate B, Ancoli-Israel S.

Clin Neuropharmacol. 2018 Nov/Dec;41(6):210-215. doi: 10.1097/WNF.0000000000000307. Review.

PMID:
30303817
12.

Cervical Dystonia and Executive Function: A Pilot Magnetoencephalography Study.

Mahajan A, Zillgitt A, Alshammaa A, Patel N, Sidiropoulos C, LeWitt PA, Bowyer S.

Brain Sci. 2018 Aug 22;8(9). pii: E159. doi: 10.3390/brainsci8090159.

13.

At last, a randomised controlled trial of apomorphine infusion.

LeWitt PA.

Lancet Neurol. 2018 Sep;17(9):732-733. doi: 10.1016/S1474-4422(18)30284-9. Epub 2018 Jul 25. No abstract available.

PMID:
30055904
14.

Pimavanserin use in a movement disorders clinic: a single-center experience.

Mahajan A, Bulica B, Ahmad A, Kaminski P, LeWitt P, Taylor D, Krstevska S, Patel N.

Neurol Sci. 2018 Oct;39(10):1767-1771. doi: 10.1007/s10072-018-3500-5. Epub 2018 Jul 21.

PMID:
30032332
15.

Comment on 'Distinct Metabolomic Signature in Cerebrospinal Fluid in Early Parkinson's Disease' by Hiller et al.

LeWitt PA.

Mov Disord. 2018 May;33(5):855. doi: 10.1002/mds.27379. Epub 2018 May 3. No abstract available.

PMID:
29722456
16.

Effect of Concomitant Medications on the Safety and Efficacy of Extended-Release Carbidopa-Levodopa (IPX066) in Patients With Advanced Parkinson Disease: A Post Hoc Analysis.

LeWitt PA, Verhagen Metman L, Rubens R, Khanna S, Kell S, Gupta S.

Clin Neuropharmacol. 2018 Mar/Apr;41(2):47-55. doi: 10.1097/WNF.0000000000000269.

17.

Recommendations of the Global Multiple System Atrophy Research Roadmap Meeting.

Walsh RR, Krismer F, Galpern WR, Wenning GK, Low PA, Halliday G, Koroshetz WJ, Holton J, Quinn NP, Rascol O, Shaw LM, Eidelberg D, Bower P, Cummings JL, Abler V, Biedenharn J, Bitan G, Brooks DJ, Brundin P, Fernandez H, Fortier P, Freeman R, Gasser T, Hewitt A, Höglinger GU, Huentelman MJ, Jensen PH, Jeromin A, Kang UJ, Kaufmann H, Kellerman L, Khurana V, Klockgether T, Kim WS, Langer C, LeWitt P, Masliah E, Meissner W, Melki R, Ostrowitzki S, Piantadosi S, Poewe W, Robertson D, Roemer C, Schenk D, Schlossmacher M, Schmahmann JD, Seppi K, Shih L, Siderowf A, Stebbins GT, Stefanova N, Tsuji S, Sutton S, Zhang J.

Neurology. 2018 Jan 9;90(2):74-82. doi: 10.1212/WNL.0000000000004798. Epub 2017 Dec 13.

18.

The Effect of Botulinum Toxin on Network Connectivity in Cervical Dystonia: Lessons from Magnetoencephalography.

Mahajan A, Alshammaa A, Zillgitt A, Bowyer SM, LeWitt P, Kaminski P, Sidiropoulos C.

Tremor Other Hyperkinet Mov (N Y). 2017 Nov 10;7:502. doi: 10.7916/D84M9H4W. eCollection 2017.

19.

Portrayal of progressive supranuclear palsy in the 16th century.

LeWitt P.

Lancet Neurol. 2017 Dec;16(12):956-957. doi: 10.1016/S1474-4422(17)30366-6. Epub 2017 Nov 14. No abstract available.

PMID:
29165255
20.

Pulmonary Safety and Tolerability of Inhaled Levodopa (CVT-301) Administered to Patients with Parkinson's Disease.

LeWitt PA, Pahwa R, Sedkov A, Corbin A, Batycky R, Murck H.

J Aerosol Med Pulm Drug Deliv. 2018 Jun;31(3):155-161. doi: 10.1089/jamp.2016.1354. Epub 2017 Nov 21.

21.

Multimodal Imaging in a Patient with Hemidystonia Responsive to GPi Deep Brain Stimulation.

Sidiropoulos C, Bowyer SM, Zillgitt A, LeWitt PA, Bagher-Ebadian H, Davoodi-Bojd E, Schwalb JM, Rammo R, Air E, Soltanian-Zadeh H.

Case Rep Neurol Med. 2017;2017:9653520. doi: 10.1155/2017/9653520. Epub 2017 Jul 4.

22.

Multicenter observational study of abobotulinumtoxinA neurotoxin in cervical dystonia: The ANCHOR-CD registry.

Trosch RM, Espay AJ, Truong D, Gil R, Singer C, LeWitt PA, Lew MF, Tagliati M, Adler CH, Chen JJ, Marchese D, Comella CL.

J Neurol Sci. 2017 May 15;376:84-90. doi: 10.1016/j.jns.2017.02.042. Epub 2017 Feb 21.

23.

Increased Oxidative Stress Markers in Cerebrospinal Fluid from Healthy Subjects with Parkinson's Disease-Associated LRRK2 Gene Mutations.

Loeffler DA, Klaver AC, Coffey MP, Aasly JO, LeWitt PA.

Front Aging Neurosci. 2017 Apr 3;9:89. doi: 10.3389/fnagi.2017.00089. eCollection 2017.

24.

Long-term follow-up of a randomized AAV2-GAD gene therapy trial for Parkinson's disease.

Niethammer M, Tang CC, LeWitt PA, Rezai AR, Leehey MA, Ojemann SG, Flaherty AW, Eskandar EN, Kostyk SK, Sarkar A, Siddiqui MS, Tatter SB, Schwalb JM, Poston KL, Henderson JM, Kurlan RM, Richard IH, Sapan CV, Eidelberg D, During MJ, Kaplitt MG, Feigin A.

JCI Insight. 2017 Apr 6;2(7):e90133. doi: 10.1172/jci.insight.90133.

25.

Metabolomic biomarkers as strong correlates of Parkinson disease progression.

LeWitt PA, Li J, Lu M, Guo L, Auinger P; Parkinson Study Group–DATATOP Investigators.

Neurology. 2017 Feb 28;88(9):862-869. doi: 10.1212/WNL.0000000000003663. Epub 2017 Feb 8.

26.

GPi vs STN deep brain stimulation for Parkinson disease: Three-year follow-up.

Sidiropoulos C, LeWitt PA, Odekerken VJ, Schuurman PR, de Bie RM.

Neurology. 2016 Aug 16;87(7):745-6. doi: 10.1212/WNL.0000000000003027. No abstract available.

PMID:
27527541
27.

Age-Related Decrease in Heat Shock 70-kDa Protein 8 in Cerebrospinal Fluid Is Associated with Increased Oxidative Stress.

Loeffler DA, Klaver AC, Coffey MP, Aasly JO, LeWitt PA.

Front Aging Neurosci. 2016 Jul 26;8:178. doi: 10.3389/fnagi.2016.00178. eCollection 2016.

28.

Neurogenic orthostatic hypotension and supine hypertension in Parkinson's disease and related synucleinopathies: prioritisation of treatment targets.

Espay AJ, LeWitt PA, Hauser RA, Merola A, Masellis M, Lang AE.

Lancet Neurol. 2016 Aug;15(9):954-966. doi: 10.1016/S1474-4422(16)30079-5. Review.

PMID:
27478953
29.

Nocardia asteroides-Induced movement abnormalities in mice: Relevance for Parkinson's disease?

Loeffler DA, LeWitt PA, Camp DM.

Mov Disord. 2016 Aug;31(8):1134-8. doi: 10.1002/mds.26711. Epub 2016 Jul 14. Review. No abstract available.

30.

Prospective evaluation of pulmonary function in Parkinson's disease patients with motor fluctuations.

Hampson NB, Kieburtz KD, LeWitt PA, Leinonen M, Freed MI.

Int J Neurosci. 2017 Mar;127(3):276-284. doi: 10.1080/00207454.2016.1194274. Epub 2016 Jun 27.

PMID:
27345931
31.

Intraoperative MRI for deep brain stimulation lead placement in Parkinson's disease: 1 year motor and neuropsychological outcomes.

Sidiropoulos C, Rammo R, Merker B, Mahajan A, LeWitt P, Kaminski P, Womble M, Zec A, Taylor D, Wall J, Schwalb JM.

J Neurol. 2016 Jun;263(6):1226-31. doi: 10.1007/s00415-016-8125-0. Epub 2016 Apr 28.

PMID:
27126457
32.

A randomized trial of inhaled levodopa (CVT-301) for motor fluctuations in Parkinson's disease.

LeWitt PA, Hauser RA, Grosset DG, Stocchi F, Saint-Hilaire MH, Ellenbogen A, Leinonen M, Hampson NB, DeFeo-Fraulini T, Freed MI, Kieburtz KD.

Mov Disord. 2016 Sep;31(9):1356-65. doi: 10.1002/mds.26611. Epub 2016 Apr 19.

PMID:
27090868
33.

Levodopa therapy for Parkinson disease: A look backward and forward.

LeWitt PA, Fahn S.

Neurology. 2016 Apr 5;86(14 Suppl 1):S3-12. doi: 10.1212/WNL.0000000000002509. Epub 2016 Apr 4. Review.

PMID:
27044648
34.

The Efficacy Profile of Rotigotine During the Waking Hours in Patients With Advanced Parkinson's Disease: A Post Hoc Analysis.

LeWitt PA, Poewe W, Elmer LW, Asgharnejad M, Boroojerdi B, Grieger F, Bauer L.

Clin Neuropharmacol. 2016 Mar-Apr;39(2):88-93. doi: 10.1097/WNF.0000000000000133.

35.

CSF Nrf2 and HSPA8 in Parkinson's disease patients with and without LRRK2 gene mutations.

Loeffler DA, Smith LM, Coffey MP, Aasly JO, LeWitt PA.

J Neural Transm (Vienna). 2016 Mar;123(3):179-87. doi: 10.1007/s00702-015-1479-0. Epub 2015 Nov 3.

PMID:
26526034
36.

New levodopa therapeutic strategies.

LeWitt PA.

Parkinsonism Relat Disord. 2016 Jan;22 Suppl 1:S37-40. doi: 10.1016/j.parkreldis.2015.09.021. Epub 2015 Sep 8. Review.

PMID:
26459662
37.

Quantitative Analysis of Voice in Parkinson Disease Compared to Motor Performance: A Pilot Study.

Silbergleit AK, LeWitt PA, Peterson EL, Gardner GM.

J Parkinsons Dis. 2015;5(3):517-24. doi: 10.3233/JPD-140526.

PMID:
26406131
38.

Expert Consensus Group report on the use of apomorphine in the treatment of Parkinson's disease--Clinical practice recommendations.

Trenkwalder C, Chaudhuri KR, García Ruiz PJ, LeWitt P, Katzenschlager R, Sixel-Döring F, Henriksen T, Sesar Á, Poewe W; Expert Consensus Group for Use of Apomorphine in Parkinson's Disease, Baker M, Ceballos-Baumann A, Deuschl G, Drapier S, Ebersbach G, Evans A, Fernandez H, Isaacson S, van Laar T, Lees A, Lewis S, Martínez Castrillo JC, Martinez-Martin P, Odin P, O'Sullivan J, Tagaris G, Wenzel K.

Parkinsonism Relat Disord. 2015 Sep;21(9):1023-30. doi: 10.1016/j.parkreldis.2015.06.012. Epub 2015 Jun 17. Review.

PMID:
26189414
39.

Successful Management of Hemorrhage-Associated Hemiballism After Subthalamic Nucleus Deep Brain Stimulation with Pallidal Stimulation: a Case Report.

Pabaney A, Ali R, Lewitt PA, Sidiropoulos C, Schwalb JM.

World Neurosurg. 2015 Oct;84(4):1176.e1-3. doi: 10.1016/j.wneu.2015.06.070. Epub 2015 Jul 9.

PMID:
26164193
40.

Effective delivery of apomorphine in the management of Parkinson disease: practical considerations for clinicians and Parkinson nurses.

Bhidayasiri R, Chaudhuri KR, LeWitt P, Martin A, Boonpang K, van Laar T.

Clin Neuropharmacol. 2015 May-Jun;38(3):89-103. doi: 10.1097/WNF.0000000000000082. Review.

PMID:
25970277
41.

The pharmacodynamics of placebo: expectation effects of price as a proxy for efficacy.

LeWitt PA, Kim S.

Neurology. 2015 Feb 24;84(8):766-7. doi: 10.1212/WNL.0000000000001294. Epub 2015 Jan 28. No abstract available.

PMID:
25632090
42.

Levodopa therapy for Parkinson's disease: Pharmacokinetics and pharmacodynamics.

LeWitt PA.

Mov Disord. 2015 Jan;30(1):64-72. doi: 10.1002/mds.26082. Epub 2014 Dec 1. Review.

PMID:
25449210
43.

Norepinephrine deficiency in Parkinson's disease: the case for noradrenergic enhancement.

Espay AJ, LeWitt PA, Kaufmann H.

Mov Disord. 2014 Dec;29(14):1710-9. doi: 10.1002/mds.26048. Epub 2014 Oct 9. Review.

PMID:
25297066
44.

SCA 17 phenotype with intermediate triplet repeat number.

Herrema H, Mikkelsen T, Robin A, LeWitt P, Sidiropoulos C.

J Neurol Sci. 2014 Oct 15;345(1-2):269-70. doi: 10.1016/j.jns.2014.07.041. Epub 2014 Jul 26. No abstract available.

PMID:
25091452
45.

Predicting the development of levodopa-induced dyskinesias: a presynaptic mechanism?

Lewitt PA, Mouradian MM.

Neurology. 2014 May 6;82(18):1574-5. doi: 10.1212/WNL.0000000000000390. Epub 2014 Apr 9.

PMID:
24719487
46.

Clinician versus machine: reliability and responsiveness of motor endpoints in Parkinson's disease.

Heldman DA, Espay AJ, LeWitt PA, Giuffrida JP.

Parkinsonism Relat Disord. 2014 Jun;20(6):590-5. doi: 10.1016/j.parkreldis.2014.02.022. Epub 2014 Mar 5.

47.

Double-blind study of the actively transported levodopa prodrug XP21279 in Parkinson's disease.

LeWitt PA, Huff FJ, Hauser RA, Chen D, Lissin D, Zomorodi K, Cundy KC.

Mov Disord. 2014 Jan;29(1):75-82. doi: 10.1002/mds.25742. Epub 2013 Dec 13.

PMID:
24339234
48.

3-hydroxykynurenine and other Parkinson's disease biomarkers discovered by metabolomic analysis.

Lewitt PA, Li J, Lu M, Beach TG, Adler CH, Guo L; Arizona Parkinson's Disease Consortium.

Mov Disord. 2013 Oct;28(12):1653-60. doi: 10.1002/mds.25555. Epub 2013 Jul 19.

PMID:
23873789
49.

Tardive dyskinesia caused by tetrabenazine.

LeWitt PA.

Clin Neuropharmacol. 2013 May-Jun;36(3):92-3. doi: 10.1097/WNF.0b013e318290cd41.

PMID:
23673911
50.

Sustained efficacy and safety of repeated incobotulinumtoxinA (Xeomin(®)) injections in blepharospasm.

Truong DD, Gollomp SM, Jankovic J, LeWitt PA, Marx M, Hanschmann A, Fernandez HH; Xeomin US Blepharospasm Study Group.

J Neural Transm (Vienna). 2013 Sep;120(9):1345-53. doi: 10.1007/s00702-013-0998-9. Epub 2013 Feb 23.

Supplemental Content

Loading ...
Support Center